Stocks and Investing Stocks and Investing
Fri, December 2, 2022
Thu, December 1, 2022
Wed, November 30, 2022
Tue, November 29, 2022

Tazeen Ahmad Maintained (SRPT) at Strong Buy with Increased Target to $138 on, Nov 29th, 2022


Published on 2024-10-28 00:21:55 - WOPRAI, Tazeen Ahmad
  Print publication without navigation


Tazeen Ahmad of B of A Securities, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $129 to $138 on, Nov 29th, 2022.

Tazeen has made no other calls on SRPT in the last 4 months.



There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 2 agree with Tazeen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $101 on, Thursday, November 3rd, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $141 on, Thursday, October 13th, 2022


These are the ratings of the 4 analyists that currently disagree with Tazeen


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $190 on, Thursday, November 3rd, 2022
  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $158 on, Thursday, November 3rd, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $171 on, Thursday, November 3rd, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $145 on, Monday, October 17th, 2022